{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:19:56Z","timestamp":1773901196266,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Jansenn Cilag Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40271-020-00413-y","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T02:02:31Z","timestamp":1586311351000},"page":"375-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir\/Cobicistat-Based Regimens: Beyond Viral Suppression"],"prefix":"10.1007","volume":"13","author":[{"given":"Andrea","family":"Antinori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria V.","family":"Cossu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Menzaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetana","family":"Sterrantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Squillace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Di Cristo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Foc\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"D\u2019Ettore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Aprea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Pontali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Scerbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Uglietti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Termini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Rucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Mancusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"413_CR1","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","volume":"4","author":"Antiretroviral Therapy Cohort Collaboration","year":"2017","unstructured":"Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349\u201356.","journal-title":"Lancet HIV."},{"key":"413_CR2","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3018(17)30053-X","volume":"4","author":"J O\u2019Connor","year":"2017","unstructured":"O\u2019Connor J, Smith C, Lampe FC, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017;4:e295\u2013302.","journal-title":"Lancet HIV."},{"key":"413_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/QAI.0000000000000813","volume":"71","author":"AN Sheth","year":"2016","unstructured":"Sheth AN, Ofotokun I, Buchacz K, et al. Antiretroviral regimen durability and success in treatment-naive and treatment-experienced patients by year of treatment initiation, United States, 1996\u20132011. J Acquir Immune Defic Syndr. 2016;71:47\u201356.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"413_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12916-016-0640-4","volume":"14","author":"JV Lazarus","year":"2016","unstructured":"Lazarus JV, Safreed-Harmon K, Barton SE, et al. Beyond viral suppression of HIV: the new quality of life frontier. BMC Med. 2016;14:94.","journal-title":"BMC Med."},{"key":"413_CR5","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/S0140-6736(19)31231-0","volume":"393","author":"P Webster","year":"2019","unstructured":"Webster P. UNAIDS survey aligns with so-called fourth 90 for HIV\/AIDS. Lancet. 2019;393:2188.","journal-title":"Lancet"},{"key":"413_CR6","doi-asserted-by":"publisher","first-page":"e1677","DOI":"10.1097\/MD.0000000000001677","volume":"94","author":"PG Clay","year":"2015","unstructured":"Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine (Baltimore). 2015;94:e1677.","journal-title":"Medicine (Baltimore)"},{"key":"413_CR7","first-page":"141","volume":"20","author":"P Domingo","year":"2018","unstructured":"Domingo P, Mateo MG, Gutierrez MDM, Vidal F. Tolerability of current antiretroviral single-tablet regimens. AIDS Rev. 2018;20:141\u20139.","journal-title":"AIDS Rev."},{"key":"413_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11136-017-1711-5","volume":"27","author":"I Toupin","year":"2018","unstructured":"Toupin I, Engler K, Lessard D, et al. Developing a patient-reported outcome measure for HIV care on perceived barriers to antiretroviral adherence: assessing the needs of HIV clinicians through qualitative analysis. Qual Life Res. 2018;27:379\u201388.","journal-title":"Qual Life Res"},{"key":"413_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijid.2018.02.015","volume":"69","author":"ASHK Kj\u00e6r","year":"2018","unstructured":"Kj\u00e6r ASHK, Rasmussen TA, Hjollund NH, Rodkjaer LO, Storgaard M. Patient-reported outcomes in daily clinical practise in HIV outpatient care. Int J Infect Dis. 2018;69:108\u201314.","journal-title":"Int J Infect Dis."},{"key":"413_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40271-015-0123-2","volume":"8","author":"J Brunetta","year":"2015","unstructured":"Brunetta J, Moreno Guill\u00e9n S, Antinori A, et al. Patient-reported outcomes after a switch to a single-tablet regimen of rilpivirine, emtricitabine, and tenofovir DF in HIV-1-positive, virologically suppressed individuals: additional findings from a randomized, open-label, 48-week trial. Patient. 2015;8:257\u201367.","journal-title":"Patient."},{"key":"413_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1742-6405-11-39","volume":"11","author":"K Tashima","year":"2014","unstructured":"Tashima K, Crofoot G, Tomaka FL, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39.","journal-title":"AIDS Res Ther."},{"key":"413_CR12","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/jac\/dkw032","volume":"71","author":"C Marzolini","year":"2016","unstructured":"Marzolini C, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71:1755\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"413_CR13","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","volume":"32","author":"JJ Eron","year":"2018","unstructured":"Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018;32:1431\u201342.","journal-title":"AIDS."},{"key":"413_CR14","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","volume":"5","author":"C Orkin","year":"2018","unstructured":"Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48\u00a0weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5:e23\u201334.","journal-title":"Lancet HIV."},{"key":"413_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/15284336.2017.1387690","volume":"18","author":"E Lathouwers","year":"2017","unstructured":"Lathouwers E, Wong EY, Luo D, Seyedkazemi S, De Meyer S, Brown K. HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies. HIV Clin Trials. 2017;18:196\u2013204.","journal-title":"HIV Clin Trials."},{"key":"413_CR16","first-page":"105","volume":"19","author":"J Mallolas","year":"2017","unstructured":"Mallolas J. Darunavir stands up as preferred HIV protease inhibitor. AIDS Rev. 2017;19:105\u201312.","journal-title":"AIDS Rev."},{"key":"413_CR17","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1517\/14656566.2015.1109632","volume":"16","author":"A Capetti","year":"2015","unstructured":"Capetti A, Cossu MV, Rizzardini G. Darunavir\/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance. Expert Opin Pharmacother. 2015;16:2689\u2013702.","journal-title":"Expert Opin Pharmacother"},{"key":"413_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40265-013-0160-x","volume":"74","author":"ED Deeks","year":"2014","unstructured":"Deeks ED. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014;74:195\u2013206.","journal-title":"Drugs."},{"issue":"Suppl. 8","key":"413_CR19","first-page":"105","volume":"21","author":"M Murray","year":"2018","unstructured":"Murray M, Hopking J, Sievers J, et al. Improvements in patient reported outcomes of dolutegravir (DTG) based second-line treatment compared to lopinavir\/ritonavir (LPV\/r) based treatment: results from the DAWNING study [abstract]. JIAS. 2018;21(Suppl. 8):105.","journal-title":"JIAS."},{"issue":"Suppl. 8","key":"413_CR20","first-page":"101","volume":"21","author":"A Oglesby","year":"2018","unstructured":"Oglesby A, Angelis A, Punekar Y, et al. Patient-reported outcomes after switching to a 2-drug regimen of dolutegravir\u2009+\u2009rilpivirine: week 100 results from the SWORD-1 and SWORD-2 Studies. JIAS. 2018;21(Suppl. 8):101.","journal-title":"JIAS."},{"issue":"Suppl. 8","key":"413_CR21","first-page":"49","volume":"21","author":"C Benson","year":"2018","unstructured":"Benson C, Simonson R, Bicer C, Dunn K. High levels of patient satisfaction during rapidly initiated therapy with darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) for treatment of HIV-1 infection through 24\u00a0weeks of the DIAMOND study [abstract]. JIAS. 2018;21(Suppl. 8):49.","journal-title":"JIAS."},{"issue":"5","key":"413_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40271-018-0322-8","volume":"11","author":"D Wohl","year":"2018","unstructured":"Wohl D, Clarke A, Maggiolo F, et al. Patient-reported symptoms over 48\u00a0weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine. Patient. 2018;11(5):561\u201373.","journal-title":"Patient."},{"key":"413_CR23","doi-asserted-by":"publisher","first-page":"f167","DOI":"10.1136\/bmj.f167","volume":"346","author":"N Black","year":"2013","unstructured":"Black N. Patient reported outcome measures could help transform health care. BMJ. 2013;346:f167.","journal-title":"BMJ"},{"key":"413_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/2229-3485.86879","volume":"2","author":"PR Deshpande","year":"2011","unstructured":"Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res. 2011;2:137\u201344.","journal-title":"Perspect Clin Res."},{"key":"413_CR25","unstructured":"European Medicines Agency. Summary of Rezolsta product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rezolsta-epar-product-information_en.pdf. Accessed 16 Mar 2020."},{"key":"413_CR26","unstructured":"HIV-TSQ guidelines. https:\/\/www.healthpsychologyresearch.com\/sites\/default\/files\/guidelines\/HIVTSQ%20Summary_rev.11.8.15.pdf. Accessed 16 Mar 2020."},{"issue":"6","key":"413_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1023\/A:1013050904635","volume":"10","author":"A Woodcock","year":"2001","unstructured":"Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res. 2001;10(6):517\u201331.","journal-title":"Qual Life Res"},{"issue":"5","key":"413_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","volume":"9","author":"A Woodcock","year":"2006","unstructured":"Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health. 2006;9(5):320\u201333.","journal-title":"Value Health."},{"issue":"Suppl. 1","key":"413_CR29","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/S0895-4356(01)00449-8","volume":"54","author":"AC Justice","year":"2001","unstructured":"Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(Suppl. 1):S77\u201390.","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"413_CR30","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1080\/09540121.2012.656567","volume":"24","author":"LG Marc","year":"2012","unstructured":"Marc LG, Wang MM, Testa MA. Psychometric evaluation of the HIV symptom distress scale. AIDS Care. 2012;24(11):1432\u201341.","journal-title":"AIDS Care."},{"issue":"Suppl. 8","key":"413_CR31","first-page":"109","volume":"21","author":"A Gori","year":"2018","unstructured":"Gori A, Antinori A, Ripamonti D, et al. Effectiveness and safety of cobicistat-boosted darunavir-based antiretroviral treatment in an Italian observational cohort: the TMC114FD1HTX4003 (ST.O.RE) study [abstract]. JIAS. 2018;21(Suppl. 8):109.","journal-title":"JIAS"},{"key":"413_CR32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/QAI.0b013e3181b628be","volume":"52","author":"MC Kempf","year":"2009","unstructured":"Kempf MC, Pisu M, Dumcheva A, Westfall AO, Kilby JM, Saag MS. Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr. 2009;52:336\u201341.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"413_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11904-018-0383-2","volume":"15","author":"EP Scully","year":"2018","unstructured":"Scully EP. Sex differences in HIV infection. Curr HIV AIDS Rep. 2018;15:136\u201346.","journal-title":"Curr HIV AIDS Rep"},{"key":"413_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/QAI.0000000000000842","volume":"71","author":"MJ Curno","year":"2016","unstructured":"Curno MJ, Rossi S, Hodges-Mameletzis I, Johnston R, Price MA, Heidari S. A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies. J Acquir Immune Defic Syndr. 2016;71:181\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"413_CR35","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/09540121.2018.1437254","volume":"30","author":"H Swan","year":"2018","unstructured":"Swan H, Reisman JI, McDannold SE, et al. The relationship between gastrointestinal symptom attribution, bothersomeness, and antiretroviral adherence among adults with HIV. AIDS Care. 2018;30(8):997\u20131003.","journal-title":"AIDS Care."},{"key":"413_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/QAI.0000000000001193","volume":"74","author":"GD Huhn","year":"2017","unstructured":"Huhn GD, Tebas P, Gallant J, et al. A randomized, open-label trial to evaluate switching to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017;74:193\u2013200.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"413_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/09540121.2015.1096890","volume":"28","author":"EL Wilkins","year":"2016","unstructured":"Wilkins EL, Cohen CJ, Trottier B, et al. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48\u00a0weeks of treatment. AIDS Care. 2016;28:401\u20138.","journal-title":"AIDS Care."},{"key":"413_CR38","unstructured":"Overton ET, Orkin C, Swindells S, et al. Monthly long-acting cabotegravir and rilpivirine is non-inferior to oral ART as maintenance therapy for HIV-1 infection: week 48 pooled analysis from the phase 3 ATLAS and FLAIR studies. In: The 10th IAS Conference on HIV Science; July 21\u201324, 2019; Mexico City, MX (Abstract 1291)."},{"key":"413_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/09540121.2018.1545990","volume":"31","author":"G Zeluf-Andersson","year":"2019","unstructured":"Zeluf-Andersson G, Eriksson LE, Sch\u00f6nnesson LN, H\u00f6ijer J, M\u00e5nehall P, Ekstr\u00f6m AM. Beyond viral suppression: the quality of life of people living with HIV in Sweden. AIDS Care. 2019;31:403\u201312.","journal-title":"AIDS Care"},{"key":"413_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00059","volume":"2","author":"CM Fares","year":"2018","unstructured":"Fares CM, Williamson TJ, Theisen MK, et al. Low concordance of patient-reported outcomes with clinical and clinical trial documentation. JCO Clin Cancer Inform. 2018;2:1\u201312.","journal-title":"JCO Clin Cancer Inform."},{"key":"413_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/09540121.2015.1080794","volume":"28","author":"F Marando","year":"2016","unstructured":"Marando F, Gualberti G, Costanzo AM, et al. Discrepancies between physician\u2019s perception of depression in HIV patients and self-reported CES-D-20 assessment: the DHIVA study. AIDS Care. 2016;28:147\u201359.","journal-title":"AIDS Care."},{"key":"413_CR42","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/jcsm.12344","volume":"9","author":"PE Penson","year":"2018","unstructured":"Penson PE, Mancini GBJ, Toth PP, et al. Introducing the \u2018Drucebo\u2019 effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9:1023\u201333.","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"413_CR43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","volume":"67","author":"J McCambridge","year":"2014","unstructured":"McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67:267\u201377.","journal-title":"J Clin Epidemiol"},{"key":"413_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1468-1293.2012.01060.x","volume":"14","author":"C Orkin","year":"2013","unstructured":"Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once daily darunavir\/ritonavir compared with lopinavir\/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013;14:49\u201359.","journal-title":"HIV Med."}],"updated-by":[{"DOI":"10.1007\/s40271-020-00425-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000}}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-020-00413-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-020-00413-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-020-00413-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T23:21:21Z","timestamp":1617837681000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-020-00413-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1007\/s40271-020-00413-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40271-020-00425-8","asserted-by":"object"}]},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"assertion":[{"value":"8 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version of this article, in Fig.\ufffd\ufffd2b the formatting on the x-axis of the graph has been published incorrectly.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Janssen-Cilag SpA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Andrea Antinori received a grant from Gilead Sciences, ViiV Healthcare, and Janssen-Cilag; he received consulting fees or honorarium from ViiV Healthcare, Janssen-Cilag, and Merck. Emanuele Foca has received consultancy fees and honoraria by several pharmaceutical companies in the field of HIV infections. Annamaria Cattelan received a grant from Janssen-Cilag and consulting fees or honorarium from ViiV Healthcare, MSD, Gilead Sciences, and Janssen-Cilag. Giordano Madeddu received consulting fees or honorarium from ViiV Healthcare, Gilead Sciences, MSD, and Janssen-Cilag; he received a speaker\u2019s fee from ViiV Healthcare, Angelini, and Pfizer. Emanuele Pontali received consulting fees or honorarium for advisory board participation for Janssen-Cilag; he received payments for training activities for Janssen-Cilag. Barbara Rossetti received consulting fees or honorarium for educational activities with REPs and a support for meeting participation. Andrea Gori received a grant from Janssen-Cilag, ViiV Healthcare, MSD, BMS, Abbvie, Gilead Sciences, Novartis, Pfizer, Astellas, AstraZeneca, and Angelini; he received consulting fees or honorarium from Janssen-Cilag, ViiV Healthcare, MSD, BMS, Abbvie, Gilead Sciences, Novartis, Pfizer, Astellas, AstraZeneca, and Angelini. Maria V. Cossu, Barbara Menzaghi, Gaetana Sterrantino, Nicola Squillace, Valentina Di Cristo, Antonella Catagna, Giancarlo Orofino, Daniela Valenti, Gabriella D\u2019Ettore, Lucia Aprea, Sergio Ferrara, Maria E. Locatelli, Paolo Scerbo, and Francesco Rucci have no conflicts of interest that are directly relevant to the content of this article. Alessia Uglietti, Roberta Termini, and Daniela Mancusi are Janssen employees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}